Insights

Global footprint Biocon operates in over 120 countries with seven manufacturing sites and 18 offices, indicating a wide potential market for partnerships, contract manufacturing, and distribution collaborations.

Biosimilars leadership A diversified biosimilars and generics portfolio with 12 biosimilars commercialized and 20+ biosimilar assets in development suggests opportunities for co-development, licensing, and scale-up manufacturing partnerships.

Expansion signals New leadership announced with Shreehas Tambe as CEO and MD from April 2026 may come with strategic shifts; a window for engaging during leadership transition with value propositions aligned to growth initiatives.

Sustainability edge Consistent inclusion in the S&P Global Sustainability Yearbook through 2026 underscores a commitment to responsible growth, appealing to partners seeking ESG-aligned supply chain and investment considerations.

Technology enablement Adoption of a modern tech stack (Azure, Tableau, Smartsheet, SharePoint, Teams) indicates readiness for digital collaboration, data-driven sourcing, and scalable IT-enabled partnerships and contract operations.

Similar companies to Biocon

Biocon Tech Stack

Biocon uses 8 technology products and services including Tableau, Microsoft SharePoint, Shopify, and more. Explore Biocon's tech stack below.

Biocon's Email Address Formats

Biocon uses at least 3 email formats:
Biocon Email FormatsExamplePercentage
First.Last@biocon.comJohn.Doe@biocon.com
98%
First.L@biocon.comJohn.D@biocon.com
1%
First.Middle@biocon.comJohn.Michael@biocon.com
1%

Frequently Asked Questions

What is Biocon's phone number?

Minus sign iconPlus sign icon
You can contact Biocon's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Biocon's stock symbol?

Minus sign iconPlus sign icon
Biocon is a publicly traded company; the company's stock symbol is BIOCON.NS.

What is Biocon's official website and social media links?

Minus sign iconPlus sign icon
Biocon's official website is biocon.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Biocon generate?

Minus sign iconPlus sign icon
As of August 2026, Biocon's annual revenue is estimated to be $1B - $10B.

What is Biocon's SIC code and NAICS code?

Minus sign iconPlus sign icon
Biocon's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Biocon have currently?

Minus sign iconPlus sign icon
As of August 2026, Biocon has approximately 12K employees across 6 continents, including Asia, North America and Europe. Key team members include Chief Executive Officer: C. K., Chief Executive Officer: E. K. and Chief Executive Officer: M. S. Explore Biocon's employee directory with LeadIQ.

What industry does Biocon belong to?

Minus sign iconPlus sign icon
Biocon operates in the Biotechnology Research industry.

What technology does Biocon use?

Minus sign iconPlus sign icon
Biocon's tech stack includes Tableau, Microsoft SharePoint, Shopify, Microsoft Entra ID, Microsoft Azure, Smartsheet, Microsoft Teams and Adobe Creative Suite.

What is Biocon's email format?

Minus sign iconPlus sign icon
Biocon's email format typically follows the pattern of First.Last@biocon.com. Find more Biocon email formats with LeadIQ.

How much funding has Biocon raised to date?

Minus sign iconPlus sign icon
As of August 2026, Biocon has raised $1.1B in funding. The last funding round occurred on Jan 12, 2026 for $520M.

When was Biocon founded?

Minus sign iconPlus sign icon
Biocon was founded in 1978.
Biocon logo

Biocon

Biotechnology ResearchKarnataka, India10001+ Employees

Biocon Limited is an India-based biotechnology research company headquartered in Electronics City, Karnataka. Publicly listed since 2004, it operates as a fully integrated, innovation-led biopharmaceutical firm serving customers in more than 120 countries. Its portfolio blends fermentation-derived small‑molecule APIs with a broad biosimilars pipeline and a growing set of novel biologics in development, aimed at chronic diseases where access to therapy is limited.

The company has achieved regulatory milestones for its biosimilars, including insulin products and Trastuzumab-based therapies such as Ogivri, co-developed with Mylan, which is approved in the US. It also leverages its subsidiary Syngene to provide discovery and development services across the life sciences sector and pursues a pipeline of patented biologics to address unmet medical needs. In March 2026 Biocon announced the appointment of Shreehas Tambe as Chief Executive Officer and Managing Director, effective April 1, 2026.

Section iconCompany Overview

Phone number
Website
biocon.com
SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
BIOCON.NS
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
1978
Employees
10001+

Section iconFunding & Financials

  • $1.1B

    Biocon has raised a total of $1.1B of funding over 3 rounds. Their latest funding round was raised on Jan 12, 2026 in the amount of $520M as a Post IPO Equity.

  • $1B - $10B

    Biocon's revenue is estimated to be in the range of $1B - $10B

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.